1. Home
  2. EXEL

as 06-20-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Founded: 1994 Country:
United States
United States
Employees: N/A City: ALAMEDA
Market Cap: 6.3B IPO Year: 2000
Target Price: $26.64 AVG Volume (30 days): 1.5M
Analyst Decision: Buy Number of Analysts: 14
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 0.64 EPS Growth: 33.33
52 Week Low/High: $18.64 - $24.34 Next Earning Date: 07-30-2024
Revenue: $1,846,646,000 Revenue Growth: 10.98%
Revenue Growth (this year): 4.58% Revenue Growth (next year): 9.87%

EXEL Daily Stock ML Predictions

Stock Insider Trading Activity of Exelixis Inc. (EXEL)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
JOHNSON DAVID EDWARD EXEL Director May 28 '24 Buy $20.76 225,000 $4,670,055.00 1,525,730 SEC Form 4
JOHNSON DAVID EDWARD EXEL Director May 28 '24 Buy $20.32 200,000 $4,063,900.00 1,300,730 SEC Form 4
PAPADOPOULOS STELIOS EXEL Director May 20 '24 Sell $21.00 11,437 $240,177.00 1,260,578 SEC Form 4
WYSZOMIERSKI JACK L EXEL Director May 13 '24 Sell $21.37 10,923 $233,424.51 338,948 SEC Form 4
Garber Alan M EXEL Director Mar 21 '24 Sell $24.01 19,205 $461,112.05 35,703 SEC Form 4
Haley Patrick J. EXEL EVP, Commercial Feb 23 '24 Sell $21.45 47,020 $1,008,579.00 384,866 SEC Form 4
JOHNSON DAVID EDWARD EXEL Director Feb 21 '24 Buy $20.70 190,000 $3,932,734.00 1,100,730 SEC Form 4
Hessekiel Jeffrey EXEL EVP, General Counsel & Sec Dec 13 '23 Sell $23.01 25,000 $575,250.00 533,345 SEC Form 4
Haley Patrick J. EXEL EVP, Commercial Dec 12 '23 Sell $22.50 14,149 $318,352.50 307,687 SEC Form 4
Haley Patrick J. EXEL EVP, Commercial Dec 12 '23 Sell $23.35 50,000 $1,167,500.00 307,687 SEC Form 4
Hessekiel Jeffrey EXEL EVP, General Counsel & Sec Nov 30 '23 Sell $22.01 25,000 $550,250.00 583,345 SEC Form 4
Hessekiel Jeffrey EXEL EVP, General Counsel & Sec Nov 30 '23 Sell $22.06 25,000 $551,500.00 558,345 SEC Form 4
JOHNSON DAVID EDWARD EXEL Director Nov 27 '23 Sell $21.61 120,409 $2,602,038.49 790,321 SEC Form 4
JOHNSON DAVID EDWARD EXEL Director Nov 27 '23 Buy $21.61 120,409 $2,602,038.49 910,730 SEC Form 4

Share on Social Networks: